The Mota 1:1 Tincture represents an established clinical benchmark for non-combustible cannabinoid therapy. Formulated on the pharmacodynamic principle of cannabinoid synergy, the 1:1 ratio pairs Delta-9-Tetrahydrocannabinol with Cannabidiol. CBD acts as a negative allosteric modulator at the CB1 receptor site, attenuating common THC-associated adverse events such as tachycardia, dizziness, or acute anxiety, while synergistically enhancing anti-inflammatory and analgesic therapeutic outcomes.

Administered sublingually, the active cannabinoids diffuse directly across the oral mucosa and into the systemic circulation through the sublingual capillary bed. This administration route bypasses initial hepatic first-pass metabolism, offering significantly higher bioavailability and a quicker therapeutic onset compared to standard oral ingestibles or capsules. In clinical practice across European medical distribution corridors—including Germany, the UK, and Poland—balanced 1:1 tinctures are standard treatment modalities for neuropathic pain, multiple sclerosis spasticity, chronic arthritic conditions, and oncology supportive care.

Technical Specifications & Certificate of Analysis (CoA)

Formulation, Sensory & Administration Profile

• Sensory Profile: Pale golden translucent oil with a clean, neutral, and mild botanical note; unflavored formulation to ensure zero allergen contamination and maximum pharmaceutical stability.

• Carrier Matrix: Pharmaceutical-grade MCT oil facilitates rapid lipid membrane transport, protects active cannabinoids from gastric acid oxidation, and maximizes systemic bio-accessibility.

• Sublingual Dosing Protocol: Place drops directly beneath the tongue using the calibrated pipette; hold for 60 to 90 seconds prior to swallowing to facilitate maximum mucosal absorption.

• Onset & Duration Profile: Systemic uptake begins within 15 to 45 minutes of sublingual administration, providing sustained therapeutic relief across a 4 to 6-hour duration window.

European Compliance, Quality Assurance & Distribution

• EU-GMP Quality Assurance: Produced, blended, and bottled in certified cleanroom manufacturing facilities meeting EU-GMP standards, ensuring strict dosing homogeneity and validated chemical shelf-life.

• Accredited Laboratory Testing: Fully analyzed by third-party ISO/IEC 17025 accredited laboratories to confirm strict adherence to Ph. Eur. limits for heavy metals (lead, arsenic, cadmium, mercury), agrochemical residues, and microbiological purity (total aerobic microbial and yeast/mold counts).

• Schengen Logistics & Documentation: Supported by a full regulatory portfolio including batch-specific release certificates, stability testing reports, and validated narcotics transfer documentation for smooth cross-border transport within European member states.

• Pharmaceutical Packaging: Bottled in ultraviolet-blocking amber glass dropper bottles fitted with child-resistant, tamper-evident dropper pipettes to safeguard against photolytic oxidation and accidental pediatric ingestion.